Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, November 11 at 2:00 PM ET

Register Free →

Supply of Calcium Trisodium Pentetate (Ca-DTPA) Sterile Injectables

Open
International

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Documents

This scope was carved out of W6369-27-A062.

The full solicitation package (1 document), including the RFP, is on the prime solicitation, not on this scope.

View the prime solicitation

Calcium Trisodium Pentetate (Ca-DTPA) ampoules

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

Posted

subcontract

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Get full access to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyGovernment of Canada → Department of National Defence
ContactsNo contacts available
OfficeN/A
Office AddressN/A
ContactsNo contact information available

Full Description

Show more
Supplies sterile solution ampoules of Calcium Trisodium Pentetate (Ca-DTPA) for prime contractors on Department of National Defence (Canada) medical countermeasure projects. Manufactures 5.0 mL ampoules containing 1,000 mg to 1,055 mg of active ingredient for intravenous injection. Requires sterile pharmaceutical manufacturing facilities and marketing authorization from Health Canada, US FDA, EMA, or an EU member state. Delivers 750 to 1,250 sterile ampoules.

Similar Contracts

Same NAICS industry code

NAICS: 325412
New
International
Calcium Trisodium Pentetate (Ca-DTPA) ampoules
Solicitation # W6369-27-A062
The Department of National Defence, through the Strategic Medical Countermeasures Program on behalf of the Canadian Forces Health Services Group, is seeking the supply of Calcium Trisodium Pentetate (Ca-DTPA) ampoules to treat Canadian Armed Forces personnel exposed to radioactive contamination involving transuranic elements. The required product must be a sterile solution for intravenous injection containing 1,000 mg to 1,055 mg of active ingredient in a 5 mL ampoule, with a minimum shelf-life of 36 months from the date of manufacture. To ensure consistency with existing stockpiles, the product must adhere to specific packaging and labelling requirements and hold valid marketing authorization from Health Canada, the FDA, the EMA, or an EU member state. The procurement is being conducted via an Advance Contract Award Notice, with Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG identified as the sole known supplier capable of meeting the technical and clinical requirements. The contract is anticipated to run from the award date until March 31, 2031, with an estimated total value of 47,500 CAD. The firm requirement consists of 750 ampoules delivered in three annual increments of 250, starting no later than March 1, 2027, and ending by March 1, 2029. Additionally, the contract includes an option for up to 500 more ampoules exercisable throughout the contract period. This procurement is subject to the Canadian Free Trade Agreement and is not subject to set-asides or the Procurement Strategy for Indigenous Business.
Department of National Defence

POSTED

about 19 hours ago

DEADLINE

in 15 days
View Details
NAICS: 325412
New
DIBBS
BISMUTH SUBSALICYLATE
Solicitation # SPE2DP-27-T-0266
This solicitation, issued by the Defense Logistics Agency (DLA) under number SPE2DP-27-T-0266, is a small business set-aside for the procurement of 55 packages of over-the-counter, sugar-free Bismuth Subsalicylate tablets. Each tablet must contain 262 mg of Bismuth Subsalicylate and 140 mg of Calcium, with each unit of issue consisting of 48 individually sealed tablets. The product has a total shelf life of 36 months, and a minimum of 31 months must remain at the time of receipt by the first government activity. To maintain product integrity, the supplies must be protected from excessive heat exceeding 104 degrees Fahrenheit or 40 degrees Celsius. The contract specifies that packaging and packing must be commercial, with each unit in a sealed container and shipped in suitable commercial exterior containers to ensure safe delivery. Marking and labeling must adhere to Medical Marking Standard No. 1, which supersedes MIL-STD-129, and preservation must follow MIL-STD-2073-1E. Delivery is required FOB Destination to the DC ARNG MED DET in Washington, DC, with a delivery lead time of 20 days. Inspection and acceptance will occur at the destination. The procurement incorporates various FAR and DFARS clauses, including requirements for safeguarding covered defense information, NIST SP 800-171 assessment, and the Buy American Act. Invoicing must be processed electronically through the Wide Area Workflow system.
MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

1 day ago

DEADLINE

in 6 days
View Details

More opportunities from Government of Canada → Department of National Defence

Same awarding agency

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS